How Korea is trying to take control of its AI future.
Updated
January 13, 2026 10:56 AM
SK Telecom Headquarters in Seoul, South Korea. PHOTO: ADOBE STOCK
SK Telecom, South Korea’s largest mobile operator, has unveiled A.X K1, a hyperscale artificial intelligence model with 519 billion parameters. The model sits at the center of a government-backed effort to build advanced AI systems and domestic AI infrastructure within Korea. This comes at a time when companies in the United States and China largely dominate the development of the most powerful large language models.
Rather than framing A.X K1 as just another large language model, SK Telecom is positioning it as part of a broader push to build sovereign AI capacity from the ground up. The model is being developed as part of the Korean government’s Sovereign AI Foundation Model project, which aims to ensure that core AI systems are built, trained and operated within the country. In simple terms, the initiative focuses on reducing reliance on foreign AI platforms and cloud-based AI infrastructure, while giving Korea more control over how artificial intelligence is developed and deployed at scale.
One of the gaps this approach is trying to address is how AI knowledge flows across a national ecosystem. Today, the most powerful AI foundation models are often closed, expensive and concentrated within a small number of global technology companies. A.X K1 is designed to function as a “teacher model,” meaning it can transfer its capabilities to smaller, more specialized AI systems. This allows developers, enterprises and public institutions to build tailored AI tools without starting from scratch or depending entirely on overseas AI providers.
That distinction matters because most real-world applications of artificial intelligence do not require massive models operating independently. They require focused, reliable AI systems designed for specific use cases such as customer service, enterprise search, manufacturing automation or mobility. By anchoring those systems to a large, domestically developed foundation model, SK Telecom and its partners are aiming to create a more resilient and self-sustaining AI ecosystem.
The effort also reflects a shift in how AI is being positioned for everyday use. SK Telecom plans to connect A.X K1 to services that already reach millions of users, including its AI assistant platform A., which operates across phone calls, messaging, web services and mobile applications. The broader goal is to make advanced AI feel less like a distant research asset and more like an embedded digital infrastructure that supports daily interactions.
This approach extends beyond consumer-facing services. Members of the SKT consortium are testing how the hyperscale AI model can support industrial and enterprise applications, including manufacturing systems, game development, robotics and autonomous technologies. The underlying logic is that national competitiveness in artificial intelligence now depends not only on model performance, but on whether those models can be deployed, adapted and validated in real-world environments.
There is also a hardware dimension to the project. Operating an AI model at the 500-billion-parameter scale places heavy demands on computing infrastructure, particularly memory performance and communication between processors. A.X K1 is being used to test and validate Korea’s semiconductor and AI chip capabilities under real workloads, linking large-scale AI software development directly to domestic semiconductor innovation.
The initiative brings together technology companies, universities and research institutions, including Krafton, KAIST and Seoul National University. Each contributes specialized expertise ranging from data validation and multimodal AI research to system scalability. More than 20 institutions have already expressed interest in testing and deploying the model, reinforcing the idea that A.X K1 is being treated as shared national AI infrastructure rather than a closed commercial product.
Looking ahead, SK Telecom plans to release A.X K1 as open-source AI software, alongside APIs and portions of the training data. If fully implemented, the move could lower barriers for developers, startups and researchers across Korea’s AI ecosystem, enabling them to build on top of a large-scale foundation model without incurring the cost and complexity of developing one independently.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.